The (Harry) Gold standard: angina,suggestion and the path to the ‘double-blind’ test and clinical pharmacology. Part 1: angina relief and suggestion

Gold H. Drug therapy in coronary disease. JAMA 1939; 112: 1–6.

Kaptchuk TJ. Intentional ignorance: blind assessment and placebo controls in medicine. Bull Hist Med 1998; 72: 389–433.

Shapiro AK Shapiro E. The Powerful Placebo: From Ancient Priest to Modern Physician. Baltimore: Johns Hopkins University Press, 1997.

Rasmussen N. The commercial drug trial in interwar America: three types of physician collaborator. Bull Hist Med 2005; 79: 50–80.

Rasmussen N. On Speed: From Benzedrine to Adderall. New York: New York University Press, 2008.

Gabriel J. The testing of sanocrysin: science, profit, and innovation in clinical trial design, 1926–1931. J Hist Med Allied Sci 2014; 69: 604–632.

Aronowitz RA. Making Sense of Illness: Science, Society, and Disease. New York: Cambridge University Press, 1998.

Brooks H. The treatment of the patient with angina pectoris. Bull N Y Acad Med 1935; 11: 442–452.

Askanazy S. Klinisches über Diuretin. Dtsch Arch Klin Med 1896; 56: 209–230.

Freedberg AS Riseman JEF Spiegl ED. Objective evidence of the efficacy of medicinal therapy in angina pectoris. Am Heart J 1941; 22: 494–518.

Gilbert NC Kerr JA. Clinical results in treatment of angina pectoris with the purine-base diuretics. JAMA 1929; 92: 201–204.

Council on Pharmacy and Chemistry. Therapeutic claims for theobromine and theophylline preparations. JAMA 1930; 94: 1306.

Evans W Hoyle C. The comparative value of drugs used in the continuous treatment of angina pectoris. Q J Med 1933; 2: 311–338.

Evans W. Journey to Harley Street. London: David Rendel Ltd, 1968.

Mendel D Silverman M.E. William Evans. Clin Cardiol 2001; 24: 487–489.

Gaddum JH. Clinical pharmacology. Proc R Soc Med 1954; 47: 195–204.

Levy RL. Management of the patient with anginal pain. N Engl J Med 1934; 211: 392–397.

Master AM. Treatment of coronary thrombosis and angina pectoris. Med Clin North Am 1935; 19: 873–891.

Master AM Jaffe HL Dack S. The drug treatment of angina pectoris due to coronary artery disease. Am J Med Sci 1939; 197: 774–782.

Gold H Kwit NT Otto H. The xanthines (theobromine and aminophylline) in the treatment of cardiac pain. JAMA 1937; 108: 2173–2179.

Council on Pharmacy and Chemistry. Limitations of claims for aminophylline and other xanthine derivatives. JAMA 1937; 108: 2203.

Massel HM. Clinical observations on the value of various xanthine derivatives in angina pectoris. J Lab Clin Med 1939; 24: 380–383.

LeRoy GV. The effectiveness of the xanthine drugs in the treatment of angina pectoris. JAMA 1941; 116: 921–925.

Elek SR Katz LN. Some clinical uses of papaverine in heart disease. JAMA 1942; 120: 434–441.

Raab W. Thiouracil treatment of angina pectoris. JAMA 1945; 128: 249–256.

Riseman JEF. The treatment of angina pectoris. N Engl J Med 1943; 229: 670–680.

Riseman JEF Brown MG. Medicinal treatment of angina pectoris. Arch Intern Med 1937; 60: 100–118.

Daston L Galison P. Objectivity. New York: Zone Books, 2010.

Benson H McCallie DP. Angina pectoris and the placebo effect. N Engl J Med 1979; 300: 1424–1429.

Gold H. Clinical Pharmacology of Cardiac Drugs: 23rd Series of Friday Afternoon Lectures at the New York Academy of Medicine [March 25, 1949]. Box 7, ff 74, Harry Gold Papers, Medical Center Archives of New York-Presbyterian/Weill Cornell, 1949.

Gold H. Some recent developments in drug therapy. North End Clinic Quarterly 1941; 2: 5–17.

Greiner T Gold H Cattell M Travell J Bakst H Rinzler SH , et al. A method for the evaluation of the effects of drugs on cardiac pain in patients with angina of effort: a study of khellin (visammin). Am J Med 1950: 9: 143–155.

Cornell Conferences on Therapy. How to evaluate a new drug. Am J Med 1954; 11: 722–727.